Based on the results of the Phase 2 Study 191622-130 \[NCT02010775\], the current Phase 2b study is designed to further evaluate the safety and efficacy of BOTOX® for the treatment of Masseter Muscle Prominence (MMP) in adults.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Percentage of Participants Who Achieved Masseter Muscle Prominence Scale (MMPS) Grade ≤ 3 at Day 90 as Assessed by the Investigator
Timeframe: Day 90
Number of Participants With at Least One Treatment-emergent Adverse Event (TEAE)
Timeframe: First dose (Day 1) to the End of Study (Up to Day 180)
Change From Baseline in Systolic Blood Pressure
Timeframe: Baseline (Day 1) to the End of Study (Up to Day 180)
Change From Baseline in Diastolic Blood Pressure
Timeframe: Baseline (Day 1) to the End of Study (Up to Day 180)
Change From Baseline in Respiratory Rate
Timeframe: Baseline (Day 1) to the End of Study (Up to Day 180)
Change From Baseline in Pulse Rate
Timeframe: Baseline (Day 1) to the End of Study (Up to Day 180) ]